Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
Clinical trial NCT04743505 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04743505
- Sponsor
- Washington University School of Medicine
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-18
- Primary completion
- 2027-01-31
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.